Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TSC-204-A0201 |
Trade Name | |
Synonyms | TSC 204-A0201|TSC204-A0201 |
Drug Descriptions |
TSC-204-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-A*02:01, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of MAGE-A1-expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C201067 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
TSC-200-A0201 + TSC-204-A0201 | TSC-200-A0201 TSC-204-A0201 | 0 | 1 |
TSC-201-B0702 + TSC-204-A0201 | TSC-201-B0702 TSC-204-A0201 | 0 | 1 |
TSC-203-A0201 + TSC-204-A0201 | TSC-203-A0201 TSC-204-A0201 | 0 | 1 |
TSC-204-A0101 + TSC-204-A0201 | TSC-204-A0101 TSC-204-A0201 | 0 | 1 |
TSC-204-A0201 | TSC-204-A0201 | 0 | 1 |
TSC-204-A0201 + TSC-204-C0702 | TSC-204-A0201 TSC-204-C0702 | 0 | 1 |